Literature DB >> 35284508

Editorial comment on: development and external validation of a model to predict overall survival in patients with resected gallbladder cancer.

Mairéad G McNamara1.   

Abstract

Entities:  

Year:  2022        PMID: 35284508      PMCID: PMC8847874          DOI: 10.21037/hbsn-2021-31

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  15 in total

1.  Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.

Authors:  John N Primrose; Richard P Fox; Daniel H Palmer; Hassan Z Malik; Raj Prasad; Darius Mirza; Alan Anthony; Pippa Corrie; Stephen Falk; Meg Finch-Jones; Harpreet Wasan; Paul Ross; Lucy Wall; Jonathan Wadsley; Jeff T R Evans; Deborah Stocken; Raaj Praseedom; Yuk Ting Ma; Brian Davidson; John P Neoptolemos; Tim Iveson; James Raftery; Shihua Zhu; David Cunningham; O James Garden; Clive Stubbs; Juan W Valle; John Bridgewater
Journal:  Lancet Oncol       Date:  2019-03-25       Impact factor: 41.316

2.  Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.

Authors:  J Bridgewater; A Lopes; H Wasan; D Malka; L Jensen; T Okusaka; J Knox; D Wagner; D Cunningham; J Shannon; D Goldstein; M Moehler; T Bekaii-Saab; M G McNamara; J W Valle
Journal:  Ann Oncol       Date:  2015-10-19       Impact factor: 32.976

3.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

Review 4.  Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis.

Authors:  Alexander A Azizi; Angela Lamarca; Mairéad G McNamara; Juan W Valle
Journal:  Crit Rev Oncol Hematol       Date:  2021-04-20       Impact factor: 6.312

5.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Edith A Perez; John A Olson; JoAnne Zujewski; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; James N Atkins; Jeffrey L Berenberg; George W Sledge
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

6.  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

Authors:  Ghassan K Abou-Alfa; Vaibhav Sahai; Antoine Hollebecque; Gina Vaccaro; Davide Melisi; Raed Al-Rajabi; Andrew S Paulson; Mitesh J Borad; David Gallinson; Adrian G Murphy; Do-Youn Oh; Efrat Dotan; Daniel V Catenacci; Eric Van Cutsem; Tao Ji; Christine F Lihou; Huiling Zhen; Luis Féliz; Arndt Vogel
Journal:  Lancet Oncol       Date:  2020-03-20       Impact factor: 41.316

7.  Development and External Validation of a Model to Predict Overall Survival in Patients with Resected Gallbladder Cancer.

Authors:  Elise A J de Savornin Lohman; T J J de Bitter; G Hannink; M F T Wietsma; E Vink-Börger; I D Nagtegaal; T J Hugh; A J Gill; N Bhimani; M Seyed Ahadi; R S van der Post; Philip R de Reuver
Journal:  Ann Surg       Date:  2021-08-13       Impact factor: 12.969

8.  Adoption of clinical risk prediction tools is limited by a lack of integration with electronic health records.

Authors:  Videha Sharma; Ibrahim Ali; Sabine van der Veer; Glen Martin; John Ainsworth; Titus Augustine
Journal:  BMJ Health Care Inform       Date:  2021-02

9.  Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.

Authors:  Andrew X Zhu; Teresa Macarulla; Milind M Javle; R Kate Kelley; Sam J Lubner; Jorge Adeva; James M Cleary; Daniel V T Catenacci; Mitesh J Borad; John A Bridgewater; William P Harris; Adrian G Murphy; Do-Youn Oh; Jonathan R Whisenant; Maeve A Lowery; Lipika Goyal; Rachna T Shroff; Anthony B El-Khoueiry; Christina X Chamberlain; Elia Aguado-Fraile; Sung Choe; Bin Wu; Hua Liu; Camelia Gliser; Shuchi S Pandya; Juan W Valle; Ghassan K Abou-Alfa
Journal:  JAMA Oncol       Date:  2021-11-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.